SJEPD031509_D1.RNA-Seq
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 9.02
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -2.46939456
- umap2_2d
- 1.916330414
- umap1_3d
- 0.038014379
- umap2_3d
- 3.605073201
- umap3_3d
- -2.533316498
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.340
- NOTCH_SIGNALING+0.300
- PI3K_AKT_MTOR_SIGNALING+0.230
- UV_RESPONSE_DN+0.210
- MITOTIC_SPINDLE+0.170
- INTERFERON_ALPHA_RESPONSE+0.110
- INTERFERON_GAMMA_RESPONSE+0.060
- HEDGEHOG_SIGNALING+0.040
- PANCREAS_BETA_CELLS+0.040
- ANDROGEN_RESPONSE+0.030
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.400
- COAGULATION-0.390
- MYC_TARGETS_V2-0.390
- HYPOXIA-0.350
- MYOGENESIS-0.330
- ESTROGEN_RESPONSE_LATE-0.300
- KRAS_SIGNALING_DN-0.300
- APICAL_JUNCTION-0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- GLYCOLYSIS-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD032426_D1.RNA-Seq | EPN | Anaplastic EPN | 0.850 |
| 2 | MDT-AP-3296 | Med | Medulloblastoma | 0.805 |
| 3 | MDT-AP-3269 | Med | Medulloblastoma | 0.779 |
| 4 | SRR8942972 | — | — | 0.779 |
| 5 | TCGA-44-5645-01A-01R-A278-07 | — | cohortMD2 | 0.777 |
| 6 | SRR25617865 | — | A | 0.766 |
| 7 | TCGA-44-6147-01A-11R-A278-07 | — | cohortMD2 | 0.758 |
| 8 | MNG59 | — | — | 0.750 |
| 9 | SRR8518258 | — | D | 0.747 |
| 10 | TCGA-BL-A0C8-01B-04R-A277-07 | — | — | 0.746 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.110 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.060 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.030 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.020 | Inavolisib | — uncovered |